M.D. Inner Mongolia Medical University, 1996

Ph.D. Peking University, 2003

M.B.A. University of South Alabama, 2012

Translational research in breast cancer and colorectal cancer, delving into the underlying mechanisms of cancer initiation and progression, while devising effective strategies to impede these processes.

Cancer drug  development and the investigation of molecular mechanisms  involving microRNA in the anti-cancereffects of nonsteroidal anti-inflammatory drugs (NSAIDs).

Cancer drug  development and the investigation of molecular mechanisms  involving microRNA in the anti-cancer effects of non-steroidal anti-inflammatory drugs (NSAIDs)

Exploring the potential of NSAIDs as novel immune modulators to enhance the response of triple negative breast cancer and colorectal cancer to immune checkpoint inhibitors.

Cancer Therapeutics , Cancer Chemoprevention, Tumor Metastasis, Cancer Drug Discovery and Development, Health Disparities, Immunotherapy

Bin Yi, Yu Xun, Hao Cheng, Qingzhao Yu, Augusto Ochoa, Adam Riker, Yaguang Xi*. 2021. Sulindac modulatesthe response of proficient MMR colorectal cancer to anti-PD-L1 immunotherapy. Molecular Cancer Therapeutics.20(7):1295-1304.

Hongyou Zhao, Bin Yi, Zhipin Liang, Ches’Nique Phillips, Hui-Yi Lin, Adam I. Riker, Yaguang Xi*. 2021. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes and Diseases. 8 (3): 320-330.

Zhipin Liang, Zhiqiang Qin, Adam Riker, Yaguang Xi*.2020. CRISPR/ Cas9 ablating viral microRNA promotes lyticreactivation of Kaposi’s sarcoma-associated herpesvirus. Biochem Biophys Res Commun. 533 (4):1400-1405.

NCBI Bibliography